How to appeal a Highmark vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Highmark-specific note: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.

What Highmark's policy requires for vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters

Cited policy: Anthem clinical guideline Lower Extremity Peripheral Arterial Disease Revascularization (BCBS plans similar)

Lifestyle-limiting claudication (Rutherford 2-3) failing >=12 wk supervised exercise + statin + antiplatelet + smoking cessation; OR critical limb-threatening ischemia (CLTI / Rutherford 4-6) with WIfI staging and ABI/TBI/TcPO2 documentation; lesion anatomically suitable for endovascular per TASC II.

How Highmark denies vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters — and how to counter it

Where Highmark pushes back: 1) Conservative therapy log incomplete; 2) Symptoms 'lifestyle' not 'limb-threatening' yet; 3) Atherectomy device deemed unnecessary alongside angioplasty.

Counter-arguments that hold up: Submit supervised exercise log >=12 wk with claudication distances; statin, antiplatelet, ACE-I, smoking cessation documentation. Rutherford / WIfI staging. ABI / TBI / TcPO2 measurements. For CLTI cite SVS Global Vascular Guidelines (Conte JVS 2019) and BEST-CLI (Farber NEJM 2022). For atherectomy cite calcium burden on imaging and DCB / DES selection. 2024 ACC/AHA/SVS Multisociety PAD Guideline (Gornik Circulation 2024).

What Highmark typically denies for vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters

Across Highmark's commercial and Medicare books, denials cluster around a small number of patterns. For vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters, expect:

• Prior auth on biologics
• PA on advanced imaging
• OON balance bills

Treatments most often denied in this category

These are the vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters treatments most often flagged for prior auth, step therapy, or medical necessity review:

• EVAR (AAA)
• F-EVAR / B-EVAR
• Open AAA repair
• TEVAR
• CEA
• CAS (transfemoral)

How to submit the appeal to Highmark

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Highmark cited in the denial.
3. File the appeal through Highmark's portal (members: https://www.highmark.com ; providers: https://www.highmark.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Highmark's prior-authorization criteria by drug: Highmark PA criteria on ApprovalHelp.